Crossover study with cisplatin or carboplatin in advanced ovarian cancer

L. Repetto, S. Chiara, S. Mammoliti, T. Guido, M. Bruzzone, V. Secondo, G. Donadio, F. Odicino, N. Ragni, P. F. Conte, R. Rosso

Research output: Contribution to journalArticlepeer-review


Fifty-seven patients who had progressed during or relapsed after randomized first-line combination chemotherapy containing cisplatin or carboplatin were entered into a crossover study in which the analog not previously assigned was administered alone as salvage treatment. Carboplatin and cisplatin were administered at doses of 400 and 100 mg/m2, respectively, every 28 days. Among the 24 patients enrolled in the cisplatin arm, 6 (25%) objective responses (ORs) (3 complete, 3 partial) were observed, whereas 3 partial responses were obtained in the 33 carboplatin-treated patient (9%). Analysis of results, according to response to first-line chemotherapy, demonstrated that the patients who progressed were sensitive only to cisplatin second-line treatment (OR: 3 12), with no responders among carboplatin-treated patients (OR: 0 11). All patients were treated on an outpatient basis and therapy-related toxic effects were mild, consisting chiefly of myelosuppression, and more frequent in the carboplatin group. In our opinion, carboplatin 400 mg/m2 per cycle is scarcely effective in patients with refractory or relapsed ovarian cancer pretreated with cisplatin regimens, whereas cisplatin 100 mg/m2 per cycle appears to be an effective salvage therapy even in patients not responding to carboplatin. The dose of carboplatin should be further escalated especially in refractory patients.

Original languageEnglish
Pages (from-to)146-149
Number of pages4
JournalGynecologic Oncology
Issue number2
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology


Dive into the research topics of 'Crossover study with cisplatin or carboplatin in advanced ovarian cancer'. Together they form a unique fingerprint.

Cite this